The Efficacy and Safety of Dapagliflozin on Renal Outcomes in Children with Chronic Kidney Disease

The Efficacy and Safety of Dapagliflozin on Renal Outcomes in Children with Chronic Kidney Disease: A Multicenter Randomized Controlled Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200608047689N4

Enrollment

Registered

2025-11-20

Start date

2025-11-21

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease, unspecified.. Chronic kidney disease, unspecified.

Interventions

Intervention 1: Intervention group: Children with CKD in the study group will receive dapagliflozin (0.1-0.2 mg/kg) daily in addition to routine treatment for 4 months. Intervention 2: Control group:

Eligibility

Sex/Gender

All

Age

1 Years to 18 Years

Inclusion criteria

Inclusion criteria: Chronic kidney disease stage 1-4

Exclusion criteria

Exclusion criteria: CKD stage 5 type 1 and type 2 diabetes mellitus Those on renal replacement therapy previous history of allergies to SGLT-2 inhibitors

Design outcomes

Primary

Measure	Time frame
Decreased GFR. Timepoint: Before intervention and 4 months after intervention. Method of measurement: laboratory result.	—

Secondary

Measure	Time frame
Adverse efffects. Timepoint: Before intervention and 4 months after intervention. Method of measurement: examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElham Bidabadi

Rasht University of Medical Sciences

bidabadi@mail.com+98 13 3372 9104

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026